MarketCapExport financials
Aeglea BioTherapeutics (AGLE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aeglea BioTherapeutics Income Statement 2025-2011 | AGLE
Brief overview of income trends at Aeglea BioTherapeutics
This overview is based on financial performance over the past five years. According to figures from Aeglea BioTherapeutics, revenue changed from 3.9 million dollars to 886 thousand dollars over five years. The five-year change reached −77.2%, while CAGR stood at −25.6%. The decline points to a contraction in the scale of the business.
Over the period, EBITDA shifted from −$45.2 million to −$242 million, a change of −434.8%. Operating performance weakened relative to revenue. EBITDA margin moved from −1161.8% to −27264%. Cost pressure reduced operating profitability.
Comparing the endpoints shows a move from −44.3 million dollars to −339 million dollars. The loss widened and increased the financial risk.
Summary assessment
The indicators point to a weaker financial profile. Caution is warranted because of a declining EBITDA margin, a softer top-line trend and limited operating profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 724 M | 82.8 M | 1.35 M | 12.5 M | 420 M | 226 M | 187 M | 104 M | 39.3 M | - | - | - | - | - |
Shares |
78.2 M | 60.3 M | 6.9 M | 3.37 M | 2.63 M | 53.4 M | 31.9 M | 20.8 M | 15.1 M | 9.79 M | - | - | - | - | - |
Historical Prices |
- | 12 | 12 | 0.4 | 4.75 | 7.87 | 7.64 | 7.49 | 5.41 | 4.35 | - | - | - | - | - |
Net Income |
-155 M | -208 M | -339 M | -83.8 M | -65.8 M | -80.9 M | -78.3 M | -44.3 M | -27.2 M | -21.7 M | -11.3 M | -10.3 M | - | - | - |
Revenue |
- | - | 886 K | 2.33 M | 18.7 M | 21.8 K | - | 3.89 M | 5.2 M | 4.63 M | 6.08 M | - | - | - | - |
Operating Income |
-210 M | -209 M | -242 M | -84.8 M | -65.6 M | -81.5 M | -80.3 M | -45.5 M | -27.7 M | -21.9 M | -11.3 M | -8.9 M | - | - | - |
Interest Expense |
29.5 M | -20.7 M | -19.1 M | -7 K | -122 K | -5 K | -63 K | -57 K | -42 K | -36 K | -2 K | - | - | - | - |
EBITDA |
-210 M | -209 M | -242 M | -83.2 M | -64.1 M | -80.5 M | -79.9 M | -45.2 M | -27.4 M | -21.8 M | -11.2 M | -7.44 M | - | - | - |
Operating Expenses |
210 M | 209 M | 243 M | 87.1 M | 84.4 M | 81.5 M | 80.3 M | 49.4 M | 32.9 M | 26.5 M | 17.4 M | - | - | - | - |
General and Administrative Expenses |
47.9 M | 45.8 M | 39.9 M | 28.5 M | 27.3 M | 21.8 M | 15.7 M | 12.6 M | 10.1 M | 8.39 M | 5.95 M | 2.07 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Aeglea BioTherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
88.1 M | 78.8 M | 78.2 M | 60.5 M | 60.4 M | 60.3 M | 60.3 M | 50.9 M | 45.3 M | 36.5 M | 36.1 M | 4.29 M | 3.82 M | 3.77 M | 2.61 M | 3.77 M | 82.2 M | 66 M | 49.4 M | 65.8 M | 65.6 M | 65.6 M | 48 M | 62.2 M | 52.9 M | 33.1 M | 29.1 M | 32.9 M | 32.8 M | 29 M | 24.1 M | 22 M | 20.6 M | 16.7 M | 16.7 M | 16.4 M | 14.1 M | 13.4 M | 13.4 M | 13.3 M | 11.8 M | 641 K | 757 K | 613 K | 586 K | 573 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-36.2 M | -69 M | - | -11.2 M | -36.7 M | -44.8 M | - | -69 M | -38.8 M | -43.9 M | - | -40.1 M | -217 M | -18.4 M | - | -18.2 M | -22.3 M | -24.4 M | - | -20.3 M | -6.83 M | -18.2 M | -22.7 M | -18 M | -21.4 M | -18.7 M | -21.5 M | -21.6 M | -18 M | -17.2 M | -14.9 M | -11.9 M | -9.41 M | -8.12 M | -6.48 M | -7.87 M | -6.63 M | -6.25 M | -5.48 M | -6.24 M | -5.43 M | -4.55 M | -3.99 M | -3.41 M | -1.43 M | -2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 688 K | 198 K | - | 174 K | 625 K | 1.36 M | - | 1.4 M | 13.7 M | - | - | - | - | - | - | - | - | - | - | - | 2.38 M | 1.51 M | 1.48 M | 1.26 M | 1.48 M | 982 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-41.6 M | -45.6 M | - | -56.9 M | -41.9 M | -53.6 M | - | -55.4 M | -44.1 M | -47.8 M | - | -18.3 M | -159 M | -18.8 M | - | -18.8 M | -22.4 M | -24.4 M | - | -20.3 M | -6.7 M | -18.2 M | -22.8 M | -18.1 M | -21.6 M | -19 M | -21.9 M | -22.1 M | -18.6 M | -17.7 M | -15.3 M | -12.2 M | -9.67 M | -8.24 M | -6.63 M | -8 M | -6.72 M | -6.33 M | -5.54 M | -6.3 M | -5.5 M | -4.57 M | -4 M | -3.42 M | -1.43 M | -2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-4.61 M | -30.4 M | - | 40.3 M | -656 K | 2.29 M | - | -18.8 M | -610 K | -483 K | - | 2.34 M | -8 K | -72 K | - | 24 K | 5 K | -30 K | - | -24 K | -52 K | -31 K | - | 2 K | -19 K | -6 K | - | -12 K | -16 K | -17 K | - | -13 K | -7 K | -17 K | - | -12 K | -12 K | -11 K | - | -9 K | -9 K | -6 K | - | -1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-41.6 M | - | - | - | - | - | - | - | - | - | - | - | - | -18.4 M | - | -17.6 M | -22.4 M | -24 M | - | -19.1 M | -6.7 M | -17.9 M | -22.8 M | -17.5 M | -21.2 M | -18.9 M | -21.9 M | -21.8 M | -18.4 M | -17.6 M | -15.3 M | -12 M | -9.52 M | -8.18 M | -6.63 M | -7.82 M | -6.61 M | -6.28 M | -5.54 M | -6.2 M | -5.43 M | -4.54 M | -4 M | -3.36 M | -1.4 M | -2.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
41.6 M | 45.6 M | - | 56.9 M | 41.9 M | 53.6 M | - | 55.4 M | 44.1 M | 47.8 M | - | 18.3 M | 160 M | 19 M | - | 18.9 M | 23 M | 25.8 M | - | 21.7 M | 20.4 M | 18.2 M | - | 18.1 M | 21.6 M | 19 M | - | 22.1 M | 18.6 M | 17.7 M | - | 12.2 M | 12 M | 9.76 M | - | 9.26 M | 8.2 M | 7.31 M | - | 7.45 M | 6.87 M | 5.43 M | - | 4.49 M | 4.86 M | 2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
16.1 M | 15.2 M | - | 11.6 M | 11.8 M | 11.9 M | - | 10.6 M | 11.5 M | 12.8 M | - | 8.58 M | 12.1 M | 5.23 M | - | 6.95 M | 7.68 M | 8.82 M | - | 6.84 M | 6.82 M | 6.35 M | - | 5.67 M | 4.69 M | 4.46 M | - | 4.31 M | 3.82 M | 3.27 M | - | 3.31 M | 2.93 M | 2.88 M | - | 3.02 M | 2.36 M | 2.36 M | - | 2.06 M | 2.45 M | 1.83 M | - | 1.36 M | 2.12 M | 847 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Aeglea BioTherapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
France
Israel
Australia
Britain
